Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab: A Case Report

被引：0

作者：

Wada, Takuma Tsuzuki ^{[1
]}

Yokota, Kazuhiro ^{[1
]}

Okada, Mariko ^{[2
]}

Ichimura, Takaya ^{[3
]}

Ueno, Takehito ^{[1
]}

Okumura, Nobuhito ^{[1
]}

Osawa, Iichiro ^{[4
]}

Inoue, Kaiji ^{[4
]}

Akiyama, Yuji ^{[1
]}

Nakazato, Yoshihiko ^{[2
]}

Sasaki, Atsushi

Yamamoto, Toshimasa ^{[2
]}

Mimura, Toshihide ^{[1
]}

机构：

[1] Saitama Med Univ, Fac Med, Dept Rheumatol & Appl Immunol, Irama, Japan

[2] Saitama Med Univ, Fac Med, Dept Neurol, Saitama, Japan

[3] Saitama Med Univ, Fac Med, Dept Pathol, Saitama, Japan

[4] Saitama Med Univ Hosp, Dept Radiol, Saitama, Japan

来源：

INTERNAL MEDICINE | 2024年

关键词：

neuromyelitis optica spectrum disorder; Castleman disease; interleukin-6; tocilizumab; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; DIAGNOSTIC-CRITERIA; EFFICACY; PLASMABLASTS; SATRALIZUMAB; AQUAPORIN-4; SAFETY;

D O I：

10.2169/internalmedicine.4503-24

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.

引用

页数：7

共 22 条

[1] Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study
Araki, Manabu
Matsuoka, Takako
Miyamoto, Katsuichi
Kusunoki, Susumu
Okamoto, Tomoko
Murata, Miho
Miyake, Sachiko
Aranami, Toshimasa
Yamamura, Takashi
[J]. NEUROLOGY, 2014, 82 (15) : 1302 - 1306
[2] CASTLEMAN B, 1956, CANCER-AM CANCER SOC, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO
[3] 2-4
[4] Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
Chihara, Norio
Aranami, Toshimasa
Sato, Wakiro
Miyazaki, Yusei
Miyake, Sachiko
Okamoto, Tomoko
Ogawa, Masafumi
Toda, Tatsushi
Yamamura, Takashi
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (09) : 3701 - 3706
[5] Elhassanien Ahmed Farag, 2013, J Pediatr Neurosci, V8, P26, DOI 10.4103/1817-1745.111418
[6] Epps Simon J, 2014, Br J Haematol, V167, P439, DOI 10.1111/bjh.13057
[7] Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan
Fujimoto, Shino
Koga, Tomohiro
Kawakami, Atsushi
Kawabata, Hiroshi
Okamoto, Shinichiro
Mizuki, Masao
Yano, Shingo
Ide, Makoto
Uno, Kazuko
Yagi, Katsumi
Kojima, Toshiyuki
Mizutani, Minoru
Tokumine, Yukihiro
Nishimoto, Norihiro
Fujiwara, Hiroshi
Nakatsuka, Shin-ichi
Shiozawa, Kazuko
Iwaki, Noriko
Masaki, Yasufumi
Yoshizaki, Kazuyuki
[J]. MODERN RHEUMATOLOGY, 2018, 28 (01) : 161 - 167
[8] A Case of Multicentric Castleman's Disease Having Lung Lesion Successfully Treated with Humanized Anti-interleukin-6 Receptor Antibody, Tocilizumab
Higuchi, Tomoaki
Nakanishi, Takashi
Takada, Kunio
Matsumoto, Mitsuyo
Okada, Makoto
Horikoshi, Hideyuki
Suzuki, Kimihiro
[J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (09) : 1364 - 1367
[9] Kim Ungsoo, 2010, Korean J Ophthalmol, V24, P256, DOI 10.3341/kjo.2010.24.4.256
[10] LEGERRAVET MB, 1991, BLOOD, V78, P2923

← 1 2 3 →